Aldeyra Therapeutics’ (ALDX) “Buy” Rating Reaffirmed at Seaport Global Securities
Other analysts have also issued reports about the company. ValuEngine raised Aldeyra Therapeutics from a sell rating to a hold rating in a report on Friday, February 2nd. Zacks Investment Research lowered Aldeyra Therapeutics from a buy rating to a hold rating in a report on Tuesday, December 26th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of Buy and an average price target of $16.79.
Shares of Aldeyra Therapeutics (NASDAQ:ALDX) opened at $8.40 on Thursday. The company has a quick ratio of 20.35, a current ratio of 20.35 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $161.55, a PE ratio of -5.96 and a beta of 0.46. Aldeyra Therapeutics has a fifty-two week low of $3.80 and a fifty-two week high of $11.90.
ILLEGAL ACTIVITY WARNING: “Aldeyra Therapeutics’ (ALDX) “Buy” Rating Reaffirmed at Seaport Global Securities” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.dailypolitical.com/2018/03/03/aldeyra-therapeutics-aldx-buy-rating-reaffirmed-at-seaport-global-securities.html.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.